Gopten

Quick links to important sections

Gopten

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gopten

Gopten is a prescription-only medicine and a single-component product whose sole active substance is Trandolapril. It is supplied as an oral dosage form in the form of hard capsules. The drug is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor, a class of agents that specifically manage blood pressure and cardiovascular function.

Property Description
Active Ingredient Trandolapril
Form Hard capsules (oral dosage form with granules)
Pharmacological Class Angiotensin-Converting Enzyme (ACE) Inhibitor
General Purpose To reduce high blood pressure (hypertension)
Origin Synthetic (and functions as a prodrug)

What is Gopten and What Type of Drug is it?

Gopten is classified as an ACE Inhibitor, a major therapeutic group used for cardiovascular management. Its active ingredient, Trandolapril, is a prodrug, meaning it requires conversion by the body's liver enzymes into its highly active metabolite, Trandolaprilat. This pharmacological property is a defining characteristic of the substance.

Trandolapril is recognized for its benefit not only in controlling systemic hypertension but also in supporting patients with left ventricular dysfunction following a heart attack. This recognition confirms the drug's role in helping to support long-term heart and vascular health.


Composition and Physical Form of Gopten

Gopten is manufactured as a single-component product and is supplied as an oral dosage form, specifically as hard gelatin capsules. These capsules contain fine granules carrying the Trandolapril compound. This capsule format is essential for ensuring a consistent and controlled delivery of the medication for effective systemic absorption.


What is the General Purpose of Trandolapril?

The central purpose of this ACE Inhibitor is to help reduce high blood pressure (hypertension) by easing the tension in blood vessel walls. Its mechanism involves inhibiting the Angiotensin-Converting Enzyme, thereby lessening the production of a key hormone that typically constricts vessels. This action reduces the resistance against which the heart must pump, effectively lowering the cardiac workload. This systematic pressure relief is an essential treatment strategy for individuals requiring ongoing cardiovascular support.

What side effects are possible with Gopten?

The safety profile of Gopten (Trandolapril), an Angiotensin-Converting Enzyme (ACE) inhibitor, is defined by regulatory documents based on classified adverse reactions, specific population constraints, and known class effects.

Officially Documented Adverse Reactions

The most frequently reported adverse reactions are commonly related to the drug's effect on blood pressure and the respiratory system, as categorized by System-Organ Class (SOC) in regulatory sources.

Frequency Tier Associated Adverse Reaction(s) SOC Examples
Common Cough, Dizziness, Headache, Diarrhea Respiratory, Nervous System, Vascular
Uncommon Fatigue, Rash, Nausea, Vomiting, Syncope Gastrointestinal, Skin, General Disorders
Rare Angioedema, Hepatotoxicity, Hyperkalemia, Neutropenia Immune System, Hepatobiliary, Blood

Serious Safety Considerations

The label highlights several clinically significant, though rare, adverse reactions and constraints:

  • Angioedema: A serious, potentially life-threatening swelling of the face, lips, tongue, or throat, which is a known risk of ACE inhibitors.
  • Fetal Toxicity: Gopten is formally contraindicated during pregnancy, particularly the second and third trimesters, due to the documented risk of injury and death to the developing fetus (a Boxed Warning in US labeling).
  • Severe Hypotension: Excessive low blood pressure may occur, particularly at the initiation of treatment or following a dose increase, or in volume-depleted patients.
  • Renal and Hepatic Risk: Patients with pre-existing renal impairment or severe hepatic impairment require close monitoring or dose adjustment, as the risk of renal dysfunction and hepatotoxicity is increased.

Safety-Related Restrictions

Official labeling strictly contraindicates the use of Trandolapril in patients with a history of angioedema related to previous ACE inhibitor use and with certain dual-therapy regimens, such as the concomitant use of aliskiren in patients with diabetes mellitus or moderate-to-severe renal impairment, or co-administration with a neprilysin inhibitor (e.g., sacubitril).

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for Gopten (Trandolapril) overdose focuses on the expected severe consequences of excessive inhibition of the Angiotensin-Converting Enzyme (ACE) and the need for immediate emergency intervention.

Overdose Scope

Element Official Regulatory Statement
Documented Overdose Presentations The most likely clinical manifestation of overdosage is severe hypotension [Source 1.2], which can lead to symptoms such as lightheadedness and fainting (syncope) [Source 1.1].
Physiological Systems Affected Primary systems affected are the Cardiovascular system, resulting in severe low blood pressure, and the Renal system, with a risk of acute renal failure and hyperkalemia [Source 2.1].
Emergency-Response Statements In case of suspected overdose, official guidance requires immediately contacting a Poison Control Center or a hospital emergency department [Source 2.5].
When Immediate Medical Help Is Required Immediate medical attention is required for severe symptoms such as fainting (passing out) [Source 1.1] or signs of a life-threatening reaction like angioedema (swelling of the face, tongue, or throat) [Source 2.1].

Official Overdose Structure

Official overdose statements:

  • No data are available with respect to overdosage in humans [Source 3.2], which directs clinical management toward treating the most probable effects.
  • Management is primarily supportive and symptomatic [Source 3.2], including the use of intravenous normal saline solution to counteract hypotension [Source 3.2].
  • Medical professionals are required to monitor vital signs, serum electrolytes, and renal function due to the associated metabolic and renal risks [Source 3.2].

Connection to the Overall Overdose Profile

The regulatory profile defines the overdose risk primarily by the pharmacological effect of profound hypotension, which requires immediate help-seeking. Official guidance mandates immediate contact with emergency services for any suspected overdose or for life-threatening reactions like angioedema. Clinical management, as officially described, must be supportive and symptomatic to stabilize the patient while closely monitoring for critical complications like hyperkalemia or renal impairment.

Therapeutic Uses of Gopten

What Gopten Treats: Main Uses and Benefits

Gopten (Trandolapril) is a prescription medication used in situations involving systemic imbalance and heightened physiological activity related to the cardiovascular system. It is commonly used to help patients manage several key conditions in which symptoms create noticeable physiological strain. Trandolapril is primarily applied in addressing conditions marked by chronic manifestations of essential hypertension, and is also relevant as supportive therapy following a myocardial infarction when left ventricular dysfunction is present, and to provide renoprotection in patients with coexisting Type 2 Diabetes and high blood pressure.

Primary Therapeutic Focus

The medication is commonly used to help with chronic conditions characterized by persistently elevated vascular pressure. This therapy is considered relevant for easing symptoms related to systemic imbalance that can damage organs over time. This provides support that may help ease the overall burden of chronic vascular risk, assisting with maintaining functional stability.

Quick Fact: Relief for Vascular Stress

Quick Fact: Relief for Vascular Stress

Trandolapril is applied in addressing conditions marked by increased physiological stress, such as those that interfere with daily functioning and contribute to functional strain on the heart and kidneys. This is relevant when supportive symptom management is appropriate, and assists with maintaining functional stability and supports the patient during difficult episodes of chronic vascular disease progression.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Who can and cannot use Gopten?

This section outlines the officially documented population eligibility and non-eligibility rules for Gopten (Trandolapril), strictly based on government regulatory labeling.


Populations for Whom Use is Contraindicated

Gopten is contraindicated (must not be used) for patients with a history of Angioedema (swelling of the face, throat, or extremities) related to any previous ACE inhibitor therapy, or those with Hereditary or Idiopathic Angioedema. It is also prohibited in patients with known Hypersensitivity to trandolapril or other ACE inhibitors. Use is prohibited with concomitant therapy of Sacubitril/Valsartan or Aliskiren (in patients with diabetes or renal impairment). Gopten is contraindicated during the Second and Third Trimesters of Pregnancy and must be discontinued as soon as pregnancy is detected.


Restricted and Non-Recommended Populations

Use is not recommended for the Pediatric Population (mathbf< 18 years) as safety and effectiveness have not been established. It is also not recommended for Nursing Women. Patients with Severe Renal Impairment or Hepatic Insufficiency are eligible but require special medical supervision and a restricted initial dose. Caution is necessary for Older Adults (ge 65 years) due to potential sensitivity, and for patients who are volume-depleted or have certain valvular heart conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Gopten (Trandolapril) is documented in official government regulatory information, outlining restrictions, timing requirements, and risk classifications.


Formal Regulatory Restrictions

Classification Interacting Agents / Conditions
Contraindicated Combinations Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) due to heightened angioedema risk. Aliskiren in patients with diabetes.
Timing-Based Rule A mandatory 36-hour wash-out period is required when switching between Trandolapril and a Neprilysin Inhibitor [Source 1.1].

Pharmacodynamic and Exposure Interactions

Interactions often involve additive effects on blood chemistry or vascular function, with the following official statements documented:

  • Potassium-Elevating Agents: Co-administration with Potassium-Sparing Diuretics (e.g., Amiloride, Triamterene), Potassium Supplements, or Potassium-Containing Salt Substitutes increases the risk of hyperkalemia.
  • Other Antihypertensives: Dual blockade of the Renin-Angiotensin System (RAS) agents (including ARBs and Aliskiren) and other antihypertensive agents may cause additive hypotensive effects or increase the risk of renal changes.
  • NSAIDs: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may attenuate the antihypertensive effect and increase the risk of renal function deterioration, particularly in volume-depleted or elderly patients.
  • mTOR Inhibitors & Lithium: Increased risk of angioedema is noted with mTOR inhibitors. Increased serum lithium levels and toxicity have been reported when co-administered with Trandolapril.

Pharmacokinetic and Food Considerations

  • Cimetidine increases the mathbfC max of the Trandolapril prodrug by approximately 44%, though this does not affect the active metabolite Trandolaprilat. Conversely, Furosemide increases the renal clearance of Trandolaprilat by about 25%.
  • Food slows the absorption of the prodrug but does not impact the overall exposure (mathbfAUC) of the active metabolite.
  • The risk of dizziness may be increased when consuming alcohol with this medication [Source 4.3].

Mechanism of Action

Gopten (trandolapril) is a pro-drug that acts by modulating the Renin-Angiotensin-Aldosterone System (RAAS), a key hormonal pathway involved in maintaining vascular tone and fluid homeostasis. Its effects are driven by interfering with the molecular components of this system.

Inhibition of the Angiotensin-Converting Enzyme (ACE)

The active form, trandolaprilat, specifically binds to and inhibits the ACE enzyme. ACE normally functions to convert the precursor hormone Angiotensin I into the vasoconstrictor, Angiotensin II. This molecular interaction suppresses the core signaling sequence of the RAAS pathway.

Decreasing Angiotensin II Signaling and Vascular Resistance

Limiting the formation of Angiotensin II influences the pathways regulating vascular tone and fluid dynamics. Reduced levels of Angiotensin II lessen its effects on vascular smooth muscle, resulting in the relaxation and widening of blood vessels (vasodilation). Inhibition of ACE also dampens the stimulatory effect on aldosterone release, which affects renal regulation of sodium and water excretion. These molecular and systemic adjustments characterize the drug's effect profile within the targeted cardiovascular pathways.

Dosage and Administration Information

How Gopten is Used: Official Administration Guidelines

Gopten (Trandolapril) is administered via the oral route as part of a chronic therapeutic plan. Its use is guided by standard protocols, which define the required administration route, dosing principles, and schedule. The medication is typically taken once daily and may be administered with or without food, establishing a flexible time of day for the dose, provided consistency is maintained by taking it at the same time each day.


Official Dosing Principles and Adjustments

Therapy generally starts with a low initial dose, which is then gradually increased, a process known as titration. Dose adjustments are standardly implemented at intervals of at least one week to allow the full therapeutic effect of the previous dose to be realized.

Indication Initial Dose (Adult) Target/Maximum Maintenance Dose
Essential Hypertension 1 mg once daily 2 mg to 4 mg once daily (up to 8 mg maximum in some labels)
Post-MI LV Dysfunction 1 mg once daily 4 mg once daily

Special Administration Conditions

Specific populations require a lower initial dose due to altered drug processing. For patients with severe renal impairment (e.g., CrCl < 30 mL/min) or hepatic cirrhosis, the initial once-daily dose is reduced to 0.5 mg. Similarly, if a patient is currently receiving diuretic therapy, the starting Trandolapril dose is reduced to 0.5 mg daily, or the diuretic is discontinued at least 72 hours prior to initiation.

Recent Clinical Evidence

Gopten: Recent Clinical Evidence


Evidence for Use in Managing High Blood Pressure (Essential Hypertension)

Clinical research for Trandolapril was studied for managing persistently high blood pressure, known as essential hypertension. These studies monitored outcomes related to systemic or functional imbalance, primarily through randomized controlled trials (RCTs). Researchers primarily monitored the degree of change in both Systolic and Diastolic Blood Pressure (BP) measurements over defined intervals, often about six weeks. Findings describe patterns observed in the studies related to BP measurements across adult populations. Evidence remains limited regarding consistent findings across all patient demographics. Differences in reported blood pressure response based on racial background in some hypertension trials highlight the limitation that results apply only to the populations studied and may not reflect consistency across all groups.


Evidence Following a Heart Attack (Left Ventricular Dysfunction Post-Myocardial Infarction)

The primary evidence base for this use comes from a large-scale, placebo-controlled Randomized Controlled Trial (RCT) known as the TRACE study. This trial was evaluated in clinically stable adult patients who had recently experienced a myocardial infarction and were identified as having impaired heart-pumping function, or Left Ventricular Dysfunction (LVD). The research examined major outcomes such as all-cause mortality and the progression to severe heart failure requiring hospitalization. The initial on-treatment follow-up lasted for two to four years.


Current Evidence Gaps and Areas of Uncertainty

Evidence highlights what is known, and what is still uncertain. The primary limitation in some trials is the use of surrogate markers, such as microalbuminuria in kidney health trials, rather than definitive long-term outcomes like end-stage renal disease. Studies concerning the relationship of age to the measured responses of Trandolapril in the pediatric population have not been performed, and specific data for this group are not available. Additionally, the initial major heart trials were conducted before current standards of care were fully adopted, meaning the full impact of Trandolapril alongside all modern recommended therapies is not directly documented in the primary evidence base.

Frequently Asked Questions (FAQ)

Common questions about Gopten (FAQ)

Q: How long does the dry cough associated with ACE inhibitors like Gopten typically last?

A: The persistent dry cough is a common side effect for ACE inhibitors like Gopten. Official product information indicates that this cough usually disappears only after the dose is lowered or the medication is stopped. The cough can persist as long as the medication is being used.

Q: Are headaches and unusual tiredness known side effects of Gopten?

A: Yes, official drug information states that headaches are a common side effect of Gopten. Additionally, unusual tiredness, or fatigue, is also reported as an expected side effect in regulatory documents.

Q: What are the warning signs of angioedema linked to taking Gopten?

A: Angioedema is a rare but serious type of swelling that can occur with Gopten. Official warnings describe swelling of the face, lips, tongue, or throat as serious signs. Other documented serious concerns include difficulty breathing or swallowing, or unexpected abdominal pain.

Q: What types of over-the-counter medicines or supplements can interact with Gopten?

A: Regulatory documents mention specific over-the-counter products that can interact with Gopten. These include certain nonsteroidal anti-inflammatory drugs (NSAIDs), potassium salts or supplements, and salt substitutes that contain potassium. These products are noted in official interaction lists.

Q: Is it necessary to avoid alcohol completely while on Gopten?

A: Official information cautions that drinking alcohol while taking Gopten may increase the risk of dizziness or feeling faint. Regulatory documents indicate that alcohol consumption increases the risk of dizziness, which is a known side effect of the medication.

Q: What are the symptoms of a serious liver problem while taking Gopten?

A: The official safety profile for Gopten describes a rare risk of hepatotoxicity (liver damage). Symptoms of a serious liver problem can include yellowing of the skin or eyes (jaundice), dark urine, or persistent nausea, vomiting, and loss of appetite.

Q: Do the side effects of Gopten usually lessen after taking the medication for a few weeks?

A: Official consumer information suggests that the initial sensation of lightheadedness sometimes experienced after the first dose may disappear. This occurs as the body adjusts to the medication. This adjustment is noted specifically for lightheadedness after the initial dose.

Q: Can taking Gopten affect a person's ability to drive or operate machinery?

A: Yes, regulatory documents advise that Gopten may affect a person's coordination, reaction time, or judgment. The official label states that affected individuals should avoid driving or operating machinery until they know how the medication affects them.

Q: Does a high-salt or low-salt diet affect how Gopten works?

A: Official drug labels state that salt substitutes containing potassium should be avoided while on Gopten, unless advised otherwise. This is due to the potential for increased blood potassium levels (hyperkalemia).

Q: How quickly does Gopten typically start to lower blood pressure?

A: Clinical pharmacology data shows that the active form of Gopten begins working relatively quickly in the body. Within about four hours of a single dose, significant inhibition of the blood pressure-regulating ACE enzyme is observed.

Q: What happens if a dose of Gopten is accidentally missed?

A: Regulatory documents contain guidance for managing a missed dose. If you remember a missed dose on the same day, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, you should skip the missed dose and continue your regular schedule, and never take double doses.

Q: Why are regular blood tests needed when taking Gopten?

A: Regular blood tests are necessary to ensure the medication is being tolerated well. Regulatory warnings state these tests monitor levels of potassium and check for changes in the function of the kidneys and liver.

Q: What specific blood markers are monitored while on Gopten?

A: When a person is taking Gopten, clinicians monitor specific blood markers related to kidney and electrolyte balance. These typically include serum potassium levels, creatinine, and Blood Urea Nitrogen (BUN), as well as general liver function tests.

Q: Is there a generic version of Gopten available?

A: Official information confirms that the active ingredient, trandolapril, is widely available as a generic tablet formulation. Trandolapril is available as a generic tablet formulation.

Q: Why is it important to stay hydrated when taking Gopten, especially in hot weather?

A: Regulatory warnings highlight the need for adequate fluid intake when taking Gopten. This is because excessive sweating or other causes of dehydration can increase the risk of low blood pressure (hypotension), and ACE inhibitors may affect the body's temperature regulation.

Q: Does Gopten contain any known allergens or sugars like lactose?

A: Official lists of inactive ingredients indicate that Trandolapril tablets generally contain lactose monohydrate (a type of sugar). This information is relevant for patients with specific sugar intolerances.

Q: Are there sulphites or other excipients in Gopten capsules that can cause allergic reactions?

A: Regulatory documents list all inactive components, known as excipients, in the formulation. These typically include ingredients such as lactose monohydrate, corn starch, and croscarmellose sodium. Patients with known allergies to excipients are advised to review the full official ingredient list.

Q: Can Gopten interact with desensitization treatments for allergies (e.g., insect stings)?

A: Yes, official warnings exist about this specific interaction. Life-threatening anaphylactoid reactions have been reported in patients receiving ACE inhibitors, like Gopten, while undergoing desensitizing treatment with venom (such as for bee or wasp stings).

Q: Why do some patients report muscle pain or weakness after starting Gopten?

A: Regulatory information indicates that Gopten may cause an increase in blood potassium levels (hyperkalemia). Muscle weakness or cramps are known symptoms associated with hyperkalemia. This is a documented clinical finding.

Q: Can Gopten cause changes in a person's sense of taste?

A: Central nervous system side effects listed in official documents include abnormal sensations (paresthesia). These sensory changes may include an altered sense of taste.

Q: What is a neutropenia and how does Gopten relate to it?

A: Neutropenia is the medical term for having a low count of white blood cells. Official regulatory information reports that neutropenia is a rare, serious side effect associated with taking Gopten and may require blood monitoring.

How should Gopten be stored and disposed of?

Official Storage and Disposal Requirements

Gopten (trandolapril) must be stored and disposed of strictly according to regulatory labeling to maintain capsule integrity and ensure public safety.

Storage Condition Constraints:

Item Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F); excursions permitted to 30 C (86 F).
Protection Keep away from heat, moisture, and direct light. Do not freeze.
Container Store in the original, tightly closed container.

Disposal and Safety:

Item Requirement
Child Safety Must be kept out of the sight and reach of children.
Disposal Discard unused or expired product via a drug take-back program. If unavailable, mix with an undesirable substance (e.g., dirt) and place in a sealed container before discarding in household trash.
Waste Rules Do not dispose of the medicine by throwing it into wastewater (sinks or toilets).

These instructions define how the medicine must be protected from environmental factors and handled safely after use, specifically addressing temperature, moisture, and proper discarding methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gopten found in:

A-Z Index: